Literature DB >> 19616097

Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice.

Zeyu Liu1, Zhongmin Guo, Guoling Wang, Dingmei Zhang, Hongxuan He, Guowei Li, Yuge Liu, Denise Higgins, Aoiffe Walsh, Leo Shanahan-Prendergast, Jiahai Lu.   

Abstract

The development of novel antiviral drugs is necessary for the prevention and treatment of a potential avian influenza pandemic. The aim of this study was to evaluate the efficacy and safety of a novel statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in a murine model. In H5N1-, H3N2- and H1N1-infected BALB/c mice, 50mug statin/200mug caffeine effectively ameliorated lung damage and inhibited viral replication and was at least as effective as oseltamivir and ribavirin. The statin/caffeine combination also appeared to be more effective when administered preventatively rather than as treatment. These findings provide justification for further research into this novel antiviral formulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616097     DOI: 10.1016/j.ejps.2009.07.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  21 in total

Review 1.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

Review 2.  The inflammatory response triggered by Influenza virus: a two edged sword.

Authors:  Luciana P Tavares; Mauro M Teixeira; Cristiana C Garcia
Journal:  Inflamm Res       Date:  2016-10-15       Impact factor: 4.575

Review 3.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

4.  Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice.

Authors:  Yohichi Kumaki; John D Morrey; Dale L Barnard
Journal:  Future Virol       Date:  2012-08       Impact factor: 1.831

5.  A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial.

Authors:  Karen E A Burns; Clarence Chant; Orla Smith; Brian Cuthbertson; Robert Fowler; Deborah J Cook; Peter Kruger; Steve Webb; Jamal Alhashemi; Guillermo Dominguez-Cherit; Carlos Zala; Gordon D Rubenfeld; John C Marshall
Journal:  Trials       Date:  2011-03-09       Impact factor: 2.279

Review 6.  Mechanisms of action and efficacy of statins against influenza.

Authors:  Parvaneh Mehrbod; Abdul Rahman Omar; Mohd Hair-Bejo; Amin Haghani; Aini Ideris
Journal:  Biomed Res Int       Date:  2014-11-11       Impact factor: 3.411

Review 7.  Insight into alternative approaches for control of avian influenza in poultry, with emphasis on highly pathogenic H5N1.

Authors:  E M Abdelwhab; Hafez M Hafez
Journal:  Viruses       Date:  2012-11-19       Impact factor: 5.048

Review 8.  Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs.

Authors:  Irene Ramos; Ana Fernandez-Sesma
Journal:  Front Immunol       Date:  2015-07-20       Impact factor: 7.561

Review 9.  Viral pathogens and acute lung injury: investigations inspired by the SARS epidemic and the 2009 H1N1 influenza pandemic.

Authors:  Carolyn M Hendrickson; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2013-08-11       Impact factor: 3.119

10.  Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Authors:  Andrea Wuestenberg; Janine Kah; Katrin Singethan; Hüseyin Sirma; Amelie Dorothea Keller; Sergio René Perez Rosal; Jörg Schrader; Christine Loscher; Tassilo Volz; Ralf Bartenschlager; Volker Lohmann; Ulrike Protzer; Maura Dandri; Ansgar W Lohse; Gisa Tiegs; Gabriele Sass
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.